Multicenter prospective study on oral management for preventing medication-related osteonecrosis of the jaw in patients receiving high-dose antiresorptive agent

Multicenter prospective study on oral management for preventing medication-related osteonecrosis of the jaw in patients receiving high-dose antiresorptive agent - Prevention of medication-related osteonecrosis of the jaw in patients receiving high-dose antiresorptive agent

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039449

Enrollment

300

Registered

2020-02-10

Start date

2019-08-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with cancer receiving high-dose antiresorptive agent

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with cancer receiving high-dose antiresorptive agent

Exclusion criteria

Exclusion criteria: edentrous patient

Design outcomes

Primary

Measure	Time frame
onset of Medication-related osteonecrosis of the jaw (MRONJ)	—

Countries

Japan

Contacts

Public ContactMasahiro Umeda

Nagasaki University Graduate School of Biomedical Sciences Department of Clinical Oral Oncology

mumeda@nagasaki-u.ac.jp81-095-819-7698

Outcome results